Format

Send to

Choose Destination
Expert Opin Investig Drugs. 2014 Mar;23(3):417-26. doi: 10.1517/13543784.2014.889114.

WT1 vaccination in acute myeloid leukemia: new methods of implementing adoptive immunotherapy.

Author information

1
Duke University Medical Center, Division of Hematologic Malignancies and Cellular Therapy , DUMC Box 3841, Durham, NC 27710 , USA +1 919 684 2287 ; +1 919 664 3309 ; lindsay.rein@duke.edu.

Abstract

INTRODUCTION:

The Wilms tumor 1 (WT1) gene was originally identified as a tumor suppressor gene that, when mutated, would lead to the development of pediatric renal tumors. More recently, it has been determined that WT1 is overexpressed in 90% of patients with acute myeloid leukemia (AML) and is mutated in approximately 10% of AML patients. WT1 plays a role in normal hematopoiesis and, in AML specifically, it has oncogenic function and plays an important role in cellular proliferation and differentiation. The ubiquity of WT1 in leukemia has lead to the development of vaccines aimed at employing the host immune system to mount a T-cell response to a known antigen.

AREAS COVERED:

In this evaluation, the authors discuss the role of WT1 in normal hematopoiesis as well as in the development of hematologic malignancies. Furthermore, the authors discuss the data supporting the development of WT1 vaccines, and the clinical trials supporting their use in patients with acute leukemia.

EXPERT OPINION:

Several small trials have been conducted which support the safety and efficacy of this therapy, although larger trials are certainly warranted. In the authors' opinion, the WT1 vaccination has potential in terms of its application as an adjuvant therapy for patients with AML who are at high risk of relapse or who have detectable minimal residual disease after initial standard therapy.

PMID:
24521058
DOI:
10.1517/13543784.2014.889114
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center